Copyright © 2003 by the European Society of Cardiology.
Clinical research
Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease
Possible role for left ventricular remodelling
a The Second Department of Internal Medicine, Hirosaki University School of Medicine, Hirosaki, Japan
b First Department of Surgery, Hirosaki University School of Medicine, Hirosaki, Japan
* Correspondence to: Ken Okumura, MD, Second Department of Internal Medicine, Hirosaki University School of Medicine, 5 Zaifu, Hirosaki 036-8562, Japan. Tel: +81-172-39-5057; Fax: +81-172-35-9190
E-mail address: okumura{at}cc.hirosaki-u.ac.jp
Received 23 January 2003; revised 13 September 2003; accepted 19 September 2003
Abstract
Aim Oxidative stress is implicated in the progression of heart failure, and matrix metalloproteinase (MMP) activity is increased in patients with congestive heart failure. We examined the role of oxidative stress on MMP activity in humans.
Methods and results We measured the MMP activity and the level of 8-iso-prostagandin F2
(8-iso-PGF2), a specific and quantitative maker of oxidant stress, in the pericardial fluid (PF) in 47 consecutive patients with coronary artery disease who underwent coronary artery bypass surgery. Zymography of PF showed bands at 92–85kDa (MMP-9) and 72–65kDa (MMP-2). The MMP activity was expressed as the ratio to MMP-2 standard. MMP-2, MMP-9 and total gelatinolysis activities were positively correlated with left ventricular end-diastolic volume index (LVEDVI), and MMP-2 and total gelatinolysis activities were also positively correlated with LV end-systolic volume index. Moreover, MMP-2, MMP-9 and total gelatinolysis activities were all positively correlated with pericardial level of 8-iso-PGF2. Also, LVDEVI was positively correlated with pericardial level of 8-iso-PGF2.
Conclusion Oxidative stress may play an important role in the regulation of MMP activity. Augmented MMP activity may be involved in the development of ventricular remodelling in patients with coronary artery disease.
Key Words: Matrix metalloproteinase • Oxidative stress • Ventricular remodelling
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- Oxidative stress in heart failure: More than just damage
- David J Grieve and Ajay M Shah
EHJ 2003 24: 2161-2163.[Extract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  P. Garvin, L. Nilsson, J. Carstensen, L. Jonasson, and M. Kristenson Plasma Levels of Matrix Metalloproteinase-9 are Independently Associated With Psychosocial Factors in a Middle-Aged Normal Population Psychosom Med, April 1, 2009; 71(3): 292 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hori and K. Nishida Oxidative stress and left ventricular remodelling after myocardial infarction Cardiovasc Res, February 15, 2009; 81(3): 457 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Braunwald Biomarkers in Heart Failure N. Engl. J. Med., May 15, 2008; 358(20): 2148 - 2159. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Uemura, M. Li, T. Tsutsumi, T. Yamazaki, T. Kawada, A. Kamiya, M. Inagaki, K. Sunagawa, and M. Sugimachi Efferent vagal nerve stimulation induces tissue inhibitor of metalloproteinase-1 in myocardial ischemia-reperfusion injury in rabbit Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2254 - H2261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Mocatta, A. P. Pilbrow, V. A. Cameron, R. Senthilmohan, C. M. Frampton, A. M. Richards, and C. C. Winterbourn Plasma Concentrations of Myeloperoxidase Predict Mortality After Myocardial Infarction J. Am. Coll. Cardiol., May 22, 2007; 49(20): 1993 - 2000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. C. Henderson, N. Tyagi, A. Ovechkin, G. K. Kartha, K. S. Moshal, and S. C. Tyagi Oxidative remodeling in pressure overload induced chronic heart failure Eur J Heart Fail, May 1, 2007; 9(5): 450 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Niu, A. Azfer, L. M. Rogers, X. Wang, and P. E. Kolattukudy Cardioprotective effects of cerium oxide nanoparticles in a transgenic murine model of cardiomyopathy Cardiovasc Res, February 1, 2007; 73(3): 549 - 559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Abe, T. Matsunaga, K. Kameda, H. Tomita, T. Fujiwara, H. Ishizaka, H. Hanada, K. Fukui, I. Fukuda, T. Osanai, et al. Increased Level of Pericardial Insulin-Like Growth Factor-1 in Patients With Left Ventricular Dysfunction and Advanced Heart Failure J. Am. Coll. Cardiol., October 3, 2006; 48(7): 1387 - 1395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Takahashi, H. Takase, T. Toriyama, T. Sugiura, Y. Kurita, R. Ueda, and Y. Dohi Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study Nephrol. Dial. Transplant., September 1, 2006; 21(9): 2507 - 2512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sato, K. Aonuma, K. Imanaka-Yoshida, T. Yoshida, M. Isobe, D. Kawase, N. Kinoshita, Y. Yazaki, and M. Hiroe Serum Tenascin-C Might Be a Novel Predictor of Left Ventricular Remodeling and Prognosis After Acute Myocardial Infarction J. Am. Coll. Cardiol., June 6, 2006; 47(11): 2319 - 2325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. A. Cameron, T. J. Mocatta, A. P. Pilbrow, C. M. Frampton, R. W. Troughton, A. M. Richards, and C. C. Winterbourn Angiotensin Type-1 Receptor A1166C Gene Polymorphism Correlates With Oxidative Stress Levels in Human Heart Failure Hypertension, June 1, 2006; 47(6): 1155 - 1161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Young and J. W. Funder Eplerenone, But Not Steroid Withdrawal, Reverses Cardiac Fibrosis in Deoxycorticosterone/ Salt-Treated Rats Endocrinology, July 1, 2004; 145(7): 3153 - 3157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J Grieve and A. M Shah Oxidative stress in heart failure: More than just damage Eur. Heart J., December 2, 2003; 24(24): 2161 - 2163. [Full Text] [PDF]
|
|